Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke...

Psychedelic Bulletin #118 – San Francisco ‘Decriminalizes’ Psychedelics

Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual...

Pain and Psychedelics – Reviewing a Newly Published Paper

Braxia Scientific to Present at H.C. Wainwright 24th Annual Global Investment...

New Psychedelic Entactogens: Designer Drugs Produce Designer Effects

PT354 – Laura Guzmán-Dávalos – Psilocybe, Microdosing, and Multigenerational Mycology

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences

Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in...

Bexson Biomedical Announces Participation in the Jeffries Innovation in Mental Health...

Load more